Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R
Institute of Endocrine Sciences, University of Milan and Fondazione Policlinico IRCCS, Milan, Italy.
Endocr Relat Cancer. 2006 Jun;13(2):455-64. doi: 10.1677/erc.1.01086.
Recently, a somatic point mutation of the B-RAF gene (V600E) has been identified as the most common genetic event in papillary thyroid carcinoma (PTC), with a prevalence variable among different series. Since discordant data on the clinico-pathologic features of B-RAF mutated PTC are present in the literature, the aim of the present co-operative study was to establish the prevalence of this genetic alteration and to perform a genotype-phenotype correlation in a large cohort of patients with PTC. To this purpose, a series of 260 sporadic PTCs with different histological variants were included in the study. The mutational analysis of the B-RAF gene was performed either by RT-PCR followed by single-stranded conformational polymorphism or by PCR and direct sequencing. Statistical analyses were obtained by means of chi2/Fisher's exact test and t-test. Overall, a heterozygous T > A transversion at nucleotide 1799 (V600E) was found in 99 out of 260 PTCs (38%). According to the histological type of the tumor, the B-RAF (V600E) mutation was present in 48.3% of cases of classic PTCs (85 out of 176), in 17.6% (nine out of 51) of follicular variants of PTCs, in 21.7% (five out of 23) in other PTC variants and in none of the ten poorly differentiated tumors. B-RAF (V600E) was significantly associated with the classic variant of PTC (P = 0.0001) and with an older age at diagnosis (P = 0.01). No statistically significant correlation was found among the presence of B-RAF (V600E) and gender, tumor node metastasis (TNM), multicentricity of the tumor, stage at diagnosis and outcome. In conclusion, the present study reports the prevalence of B-RAF (V600E) (38%) in the largest series of sporadic PTCs, including 260 cases from three different Italian referring centers. This prevalence is similar to that calculated by pooling together all data previously reported, 39.6% (759 out of 1914 cases), thus indicating that the prevalence of this genetic event lies around 38-40%. Furthermore, B-RAF (V600E) was confirmed to be associated with the papillary growth pattern, but not with poorer differentiated PTC variants. A significant association of B-RAF mutation was also found with an older age at diagnosis, the mutation being very rare in childhood and adolescent PTCs. Finally, no correlation was found with a poorer prognosis and a worse outcome after a median follow-up of 72 months.
最近,B-RAF基因的一种体细胞点突变(V600E)已被确定为甲状腺乳头状癌(PTC)中最常见的基因事件,其在不同系列中的发生率有所不同。由于文献中存在关于B-RAF突变型PTC临床病理特征的不一致数据,本合作研究的目的是确定这种基因改变的发生率,并在一大群PTC患者中进行基因型-表型相关性分析。为此,本研究纳入了一系列260例具有不同组织学变异的散发性PTC。通过逆转录聚合酶链反应(RT-PCR)后进行单链构象多态性分析或通过聚合酶链反应(PCR)和直接测序对B-RAF基因进行突变分析。通过卡方检验/费舍尔精确检验和t检验进行统计分析。总体而言,在260例PTC中有99例(38%)在核苷酸1799处发现杂合的T>A颠换(V600E)。根据肿瘤的组织学类型,B-RAF(V600E)突变在48.3%的经典型PTC病例(176例中的85例)中存在,在17.6%(51例中的9例)的PTC滤泡变异型中存在,在21.7%(23例中的5例)的其他PTC变异型中存在,而在10例低分化肿瘤中均未发现。B-RAF(V600E)与PTC的经典变异型显著相关(P = 0.0001),且与诊断时年龄较大相关(P = 0.01)。在B-RAF(V600E)的存在与性别、肿瘤淋巴结转移(TNM)、肿瘤多中心性、诊断分期和预后之间未发现统计学上的显著相关性。总之,本研究报告了在最大系列的散发性PTC(包括来自意大利三个不同转诊中心的260例病例)中B-RAF(V600E)的发生率为38%。这一发生率与汇总先前报道的所有数据计算得出的发生率39.6%(1914例中的759例)相似,因此表明这一基因事件的发生率约为38%-40%。此外,B-RAF(V600E)被证实与乳头状生长模式相关,但与低分化PTC变异型无关。还发现B-RAF突变与诊断时年龄较大显著相关,该突变在儿童和青少年PTC中非常罕见。最后,在中位随访72个月后,未发现与预后较差和结局较差相关。